Business Wire

ShadowDragon Sets a New Standard in Link Analysis, Monitoring, & OSINT by Launching Multilingual Suite

10.2.2025 16:21:00 CET | Business Wire | Press release

Share

ShadowDragon Horizon - Empowering Global Investigations in Spanish, French, Italian, German—and More Languages on the Horizon

ShadowDragon, a leader in digital investigations and open-source intelligence (OSINT) solutions, today announced the launch of Horizon in multiple languages. Effective immediately, this flagship tool—previously available in English—is now fully localized in Spanish, French, Italian, and German, with additional languages slated for release in the coming months. By expanding language support, ShadowDragon becomes the first in the industry to offer a comprehensive suite of advanced OSINT capabilities designed to serve a wide range of global investigators, law enforcement, and intelligence agencies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207507777/en/

“ShadowDragon has always led the way in building robust OSINT solutions that keep pace with today’s complex global landscape,” said Daniel Clemens, CEO and Founder of ShadowDragon. “By providing our solutions in multiple languages, we reaffirm our commitment to supporting investigations, data scientists, business intelligence, and robust due diligence processes around the world—particularly in regions where language barriers have historically affected use of advanced data visualization tools. We spent a long time building this component to allow analysts to collect, analyze and investigate data and tell the story in their own language.”

Why This Matters for Global Investigations

  1. Accelerated Case Resolution
    With user interfaces, documentation, and workflows now available in Spanish, French, Italian, and German, local and cross-border investigative teams can focus on gathering actionable intelligence — leading to quicker resolutions.
  2. Enhanced Collaboration Across Borders
    International investigations often involve partners from diverse linguistic backgrounds. Harmonizing data and workflows in multiple languages removes communication hurdles, yielding more reliable intelligence and smoother cooperation.
  3. Industry-First Multilingual OSINT Leader
    As the first OSINT provider to fully localize its core offerings across these major languages, ShadowDragon sets a new standard for accessibility and operational readiness in digital investigations.

Commitment to Global Customers

This launch underscores ShadowDragon’s long-term dedication to serving a diverse, international client base that requires cutting-edge OSINT solutions. Users can rely on in-language technical support, ongoing product updates, and comprehensive educational resources to help them get the most out of these new language capabilities from day one.

About ShadowDragon

ShadowDragon provides comprehensive digital tools for modern investigations, open source intelligence collection, tailored monitoring, and investigative platform for cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open-source intelligence (OSINT) from over 200 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for good.”

For more information on ShadowDragon’s multilingual product suite or upcoming language releases, visit www.shadowdragon.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250207507777/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye